Mark Leuchtenberger
CEO
SpyBiotech
SpyBiotech is a clinical-stage biotechnology company utilizing its proprietary protein superglue technology, SpyTag/SpyCatcher, to develop vaccines against infectious diseases and cancer. The company focuses on creating effective vaccines for conditions like cytomegalovirus, which currently lacks adequate prevention and treatment options.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$39.9MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Sumi Biswas
President & CSO
Product
Problem
Many viral, bacterial, and parasitic infectious diseases, as well as cancers, lack effective vaccine options, hindering disease prevention and treatment. Cytomegalovirus (CMV), a widespread disease with life-threatening implications, particularly for babies and children, currently lacks effective treatment or prevention.
Solution
SpyBiotech is developing vaccines against infectious diseases and cancer using its proprietary protein superglue technology, SpyTag/SpyCatcher. This technology enables the creation of safe and effective vaccines with greater ease and speed. The company is focused on addressing major human health challenges, including the development of a novel vaccine against CMV.
Target Audience
The primary target audience includes individuals at risk of infectious diseases and cancer, particularly babies and children at risk of cytomegalovirus (CMV).
Features
- Utilizes SpyTag/SpyCatcher protein superglue technology for vaccine development.
- Focuses on creating vaccines for infectious diseases and cancer.
- Developing a novel vaccine against cytomegalovirus (CMV).